Extrapulmonary Mycobacterium abscessus Infections, France, 2012-2020¹.

IF 7.2 2区医学 Q1 IMMUNOLOGY

Emerging Infectious Diseases Pub Date : 2024-11-01 DOI:10.3201/eid3011.240459

Benoît Heid-Picard, Faiza Mougari, Anne Pouvaret, Fanny Lanternier, Zeina Awad, Emmanuelle Bille, Olivier Lortholary, Emmanuelle Cambau

{"title":"Extrapulmonary Mycobacterium abscessus Infections, France, 2012-20201.","authors":"Benoît Heid-Picard, Faiza Mougari, Anne Pouvaret, Fanny Lanternier, Zeina Awad, Emmanuelle Bille, Olivier Lortholary, Emmanuelle Cambau","doi":"10.3201/eid3011.240459","DOIUrl":null,"url":null,"abstract":"Mycobacterium abscessus infection is challenging to treat. Extrapulmonary M. abscessus infections (EP-MAB) are less common than pulmonary M. abscessus infections. To evaluate treatment regimens, we retrospectively analyzed consecutive microbiologically confirmed EP-MAB cases diagnosed in France during 2012-2020. We studied 45 patients with EP-MAB, including 14 bone and joint infections, 10 skin and soft tissue infections, and 8 lymph node infections. Most (62%) patients had no reported immunodeficiency. In 27 patients, EP-MAB followed healthcare-associated (44%) or environmental (16%) injuries. Of the 45 isolates, 25 were subspecies abscessus, 10 bolletii, and 9 massiliense; 1 was unidentified. Cure was achieved for 36 (80%) patients who received a median antimicrobial regimen of 6 months; 22 (55%) also underwent surgery. Four patients died, and 5 were unavailable for follow-up. EP-MAB predominantly affects immunocompetent patients after an injury; outcomes are favorable. We propose a >6-month regimen of antimicrobial therapy with consideration for surgery and regular patient reassessment.","PeriodicalId":11595,"journal":{"name":"Emerging Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":7.2000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521186/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Emerging Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3201/eid3011.240459","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Mycobacterium abscessus infection is challenging to treat. Extrapulmonary M. abscessus infections (EP-MAB) are less common than pulmonary M. abscessus infections. To evaluate treatment regimens, we retrospectively analyzed consecutive microbiologically confirmed EP-MAB cases diagnosed in France during 2012-2020. We studied 45 patients with EP-MAB, including 14 bone and joint infections, 10 skin and soft tissue infections, and 8 lymph node infections. Most (62%) patients had no reported immunodeficiency. In 27 patients, EP-MAB followed healthcare-associated (44%) or environmental (16%) injuries. Of the 45 isolates, 25 were subspecies abscessus, 10 bolletii, and 9 massiliense; 1 was unidentified. Cure was achieved for 36 (80%) patients who received a median antimicrobial regimen of 6 months; 22 (55%) also underwent surgery. Four patients died, and 5 were unavailable for follow-up. EP-MAB predominantly affects immunocompetent patients after an injury; outcomes are favorable. We propose a >6-month regimen of antimicrobial therapy with consideration for surgery and regular patient reassessment.

查看原文本刊更多论文

肺外脓肿分枝杆菌感染，法国，2012-20201。

脓肿分枝杆菌感染的治疗具有挑战性。肺外脓肿分枝杆菌感染（EP-MAB）比肺内脓肿分枝杆菌感染少见。为了评估治疗方案，我们回顾性分析了 2012-2020 年间在法国确诊的经微生物学确诊的 EP-MAB 连续病例。我们研究了 45 例 EP-MAB 患者，其中包括 14 例骨和关节感染、10 例皮肤和软组织感染以及 8 例淋巴结感染。大多数患者（62%）未报告有免疫缺陷。在27名患者中，EP-MAB是在与医疗保健相关的伤害（44%）或环境伤害（16%）后发生的。在 45 个分离株中，25 个为脓肿亚种，10 个为博列蒂亚种，9 个为马西利亚斯亚种，1 个未确定。36名（80%）患者接受了为期6个月的中位抗菌治疗，其中22名（55%）患者接受了手术治疗。4名患者死亡，5名患者无法接受随访。EP-MAB 主要影响受伤后免疫功能正常的患者；疗效良好。我们建议采用为期 6 个月以上的抗菌治疗方案，并考虑手术和定期对患者进行重新评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Emerging Infectious Diseases 医学-传染病学

CiteScore

17.30

自引率

1.70%

发文量

505

审稿时长

1 months

期刊介绍： Emerging Infectious Diseases is a monthly open access journal published by the Centers for Disease Control and Prevention. The primary goal of this peer-reviewed journal is to advance the global recognition of both new and reemerging infectious diseases, while also enhancing our understanding of the underlying factors that contribute to disease emergence, prevention, and elimination. Targeted towards professionals in the field of infectious diseases and related sciences, the journal encourages diverse contributions from experts in academic research, industry, clinical practice, public health, as well as specialists in economics, social sciences, and other relevant disciplines. By fostering a collaborative approach, Emerging Infectious Diseases aims to facilitate interdisciplinary dialogue and address the multifaceted challenges posed by infectious diseases.